Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-10-15
2010-06-29
Saeed, Kamal A (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07745643
ABSTRACT:
The present invention provides cyclic nitro compounds, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4765539 (1988-08-01), Noakes et al.
patent: 5112598 (1992-05-01), Biesalski
patent: 5336784 (1994-08-01), Hiskey et al.
patent: 5556611 (1996-09-01), Biesalski
patent: 5580988 (1996-12-01), Dave
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5950619 (1999-09-01), van der Linden et al.
patent: 5954047 (1999-09-01), Armer et al.
patent: 5970974 (1999-10-01), Van Der Linden et al.
patent: 6245799 (2001-06-01), Asselin et al.
patent: 6407236 (2002-06-01), Baraldi et al.
patent: 7163958 (2007-01-01), Earl et al.
patent: 9532715 (1995-12-01), None
patent: 9916436 (1999-04-01), None
patent: 9959575 (1999-11-01), None
patent: 2004032864 (2004-04-01), None
patent: 2004098538 (2004-11-01), None
patent: 2004113281 (2004-12-01), None
patent: 2005046661 (2005-05-01), None
patent: 2007022121 (2007-02-01), None
patent: 2007022225 (2007-02-01), None
Archibald, T.G., et al., “Synthesis and X-ray Crystal Structure of 1,3,3-Trinitroazetidine,” J. Org. Chem, vol. 55, 1990, pp. 2920-2924.
Bamba, Morifere, et al., “Release Mechanisms in Gelforming Sustained Release Preparations,” Int. J. Pharm., vol. 2, 1979, pp. 307-315.
Chawla, Garima, et al., “Challenges in Polymorphism of Pharmaceuticals,” CRIPS, vol. 5, No. 1, Jan.-Mar. 2004, pp. 9-12.
Dave, Paritosh R., “Acylative Dealkylation of N-tert-Butyl-3-substituted Azetidines: Facile Access to [1.1.0] Azabicyclobutane, 3-Hydroxyazetidinium Hydrochloride, and 3-Azetidinones,” J. Org. Chem., vol. 61, 1996, pp. 5453-5455.
During, Matthew J., et al., “Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization,” Annals of Neurology, vol. 25, No. 4, Apr. 1989, pp. 351-356.
Huguenin, Sandra, et al., “Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines,” Cancer Letters, vol. 218, 2005, pp. 163-170.
Langer, Robert, “New Methods of Drug Delivery,” Science, New Series, vol. 249, No. 4976, Sep. 28, 1990, pp. 1527-1533.
Levy, Robert J., “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate,” Science, New Series, vol. 228, No. 4696, Apr. 12, 1985, pp. 190-192.
Naimi, Ebrahim, et al., “Synthesis of 3′- and 5′-Nitrooxy Pyrimidine Nucleoside Nitrate Esters: “Nitric Oxide Donor” Agents for Evaluation as Anticancer and Antiviral Agents,” J. Med. Chem., vol. 46, 2003, pp. 995-1004.
Newman, Ann W., et al., “Solid-state analysis of the active pharmaceutical ingredient in drug products,” DDT, vol. 8, No. 19, Oct. 2003, pp. 898-905.
Raleigh, R.D., Verschoyle, C., et al., “Pharmacokinetics of Isotretinoin (ISO) in Rats Following Oral Dosing or Aerosol Inhalation,” British J. Cancer, vol. 80, Suppl. 2, 96, 1999, p. 269.
Verma, R.K., et al., “Osmotically Controlled Oral Drug Delivery,” Drug Dev. Ind. Pharm., vol. 26, No. 7, 2000, pp. 695-708.
Alderman, D.A., “A Review of Cellulose Ethers in Hydrophilic Matrices for Oral Controlled-Release Dosage Forms,” Int. J. Pharm. Tech. & Prod. Mfr., vol. 5, No. 3, pp. 1-9, 1984.
Howard, Matthew A., III, et al., “Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits,” J. Neurosurg., vol. 71, pp. 105-112, 1989.
Langer, Robert, et al., “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review,” JMS—Rev. Macromol. Chem. Phys., Ch. 23, pp. 61-126, 1983.
Langer, Robert S., et al., eds., “Medical Applications of Controlled Release,” vol. 1, Classes of Systems, Ch. 2, pp. 42-67, CRC Press, Inc., Boca Raton, FL, copyright 1984.
Muehlstaedt et al., caplus an 1976:89768.
Remington, “The Science and Practice of Pharmacy,” 19th Edition, vol. II, pp. 1495-1562, 1577-1614, and 1660-1692, Mack Publishing Company, Easton, PA, 1995.
Rosenthal, David I., “A Phase I Single-Dose Trial of Gadolinium Texaphyrin (Gd-Tex), a Tumor Selective Radiation Sensitizer Detectable by Magnetic Resonance Imaging,” Clinical Cancer Research, vol. 5, No. 4, pp. 739-745, Apr. 1999.
Sauder, Christopher D., “A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery,” The New England Journal of Medicine, vol. 321, No. 9, pp. 574-579, Aug. 31, 1989.
Sefton, Michael V., “Implantable Pumps,” CRC Crit. Rev. Biomed. Eng., vol. 14, No. 3, pp. 201-237, 1987.
Smolen, Victor F., et al., eds., “Controlled Drug Bioavailability,” vol. 1, Drug Product Design and Performance, Ch. 7, pp. 203-237, John Wiley & Sons, New York, NY, copyright 1984.
Treat, Joseph, et al., “Liposome Encapsulated Doxorubicin Preliminary Results of Phase I and Phase II Trials,” Liposomes in the Therapy of Infectious Diseases and Cancer, Proceedings of the Ciba-Geigy-Squibb-UCLA Colloquium at Lake Tahoe, CA, Feb. 16-20, 1988, pp. 353-365.
Goodson, J. Max, “Dental Applications,” Chapter 6 of Medical Applications of Controlled Release, vol. II, pp. 115-138, CRC Press, Inc., Boca Raton, FL, copyright 1984.
Jia, Q., et al., “NO donors with anticancer activity,” Expert Opinion on Therapeutic Patents, vol. 12, No. 6 (2002), pp. 819-826, Great Britain.
Konovalova, N.P., et al., “Nitric oxide donor increases the efficiency of cytostatic therapy and retards the development of drug resistance,” Nitric Oxide, vol. 8, No. 1 (Feb. 2003), pp. 59-64.
Ling, C., et al., “Phase I study of CM-Na combined with concurrent radiochemotherapy for advanced esophageal carcinoma (abstract),” Chinese Journal of Cancer, vol. 24, No. 5 (May 2005), (U.S. National Library of Medicine, Bethesda, MD, May 2005).
Sandler, G., “Clinical evaluation of propatylnitrate in angina pectoris,” British Medical Journal, vol. 2, No. 5269 (Dec. 30, 1961), pp. 1741-1744.
Stamler, J.S., et al., “Inhaled ethyl nitrite gas for persistent pulmonary hypertension in infants,” The Lancet, Lancet Limited, vol. 360, No. 9350 (Dec. 21, 2002), p. 2077, Great Britain.
Electrochemical Oxidation of Alkylnitro Compounds PP-1345, A SERDP ‘SEED’ Activity, initial submission Jun. 30, 2004; amended Aug. 17, 2004; points of contact Scott K Lusk and Alan N. Green.
Cannizzo Louis F.
Velarde Stephen P.
Wardle Robert B.
Warner Kirstin F.
Alliant Techsystems Inc.
Saeed Kamal A
Shterengarts Samantha L
TraskBritt
LandOfFree
Methods of synthesizing cyclic nitro compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of synthesizing cyclic nitro compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of synthesizing cyclic nitro compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4192531